|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600119350 |
|
最近更新日期: Date of Last Refreshed on: |
2026-02-26 08:36:28 |
|
注册时间: Date of Registration: |
2026-02-26 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于图像识别技术的Bath强直性脊柱炎测量指数智能评估方法 |
|
Public title: |
Intelligent Assessment Method for Bath Ankylosing Spondylitis Metrology Index Based on Image Recognition Technology |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于图像识别技术的Bath强直性脊柱炎测量指数智能评估方法 |
|
Scientific title: |
Intelligent Assessment Method for Bath Ankylosing Spondylitis Metrology Index Based on Image Recognition Technology |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈玉铃 |
研究负责人: |
陈玉铃 |
|
Applicant: |
Yuling Chen |
Study leader: |
Yuling Chen |
|
申请注册联系人电话: Applicant telephone: |
+86 189 5993 1357 |
研究负责人电话:
Study leader's |
+86 189 5993 1357 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
anky6750119@163.com |
研究负责人电子邮件: Study leader's E-mail: |
anky6750119@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
深圳市光明区新湖街道圳园路628号 |
研究负责人通讯地址: |
深圳市光明区新湖街道圳园路628号 |
|
Applicant address: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China, |
Study leader's address: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China, |
|
申请注册联系人邮政编码: Applicant postcode: |
518107 |
研究负责人邮政编码: Study leader's postcode: |
518107 |
|
申请人所在单位: |
中山大学附属第七医院 |
||
|
Applicant's institution: |
The Seventh Affiliated Hospital, Sun Yat-sen University |
||
|
研究负责人所在单位: |
中山大学附属第七医院 |
||
|
Affiliation of the Leader: |
The Seventh Affiliated Hospital, Sun Yat-sen University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY-2025-067-01; KY-2025-067-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中山大学附属第七医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the Seventh Affiliated Hospital, Sun Yat-sen University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-03-04 00:00:00 | ||
|
伦理委员会联系人: |
唐燕 |
||
|
Contact Name of the ethic committee: |
Yan Tang |
||
|
伦理委员会联系地址: |
深圳市光明区新湖街道圳园路628号 |
||
|
Contact Address of the ethic committee: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China, 518107 |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 755 8120 7260 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
tangyan2@sysush.com |
|
研究实施负责(组长)单位: |
中山大学附属第七医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Seventh Affiliated Hospital, Sun Yat-sen University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
深圳市光明区新湖街道圳园路628号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.628, Zhenyuan Rd, Guangming (New) Dist., Shenzhen, China, 518107 |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
NONE |
||||||||||||||||||||||
|
研究疾病: |
中轴型脊柱炎关节炎 |
||||||||||||||||||||||
|
Target disease: |
Ankylosing Spondylitis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
诊断试验新技术临床试验 | ||||||||||||||||||||||
|
Study phase: |
Diagnostic New Technique Clincal Study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
1. 主要研究目的:验证基于图像处理技术的BASMI自动化测量系统在测量中轴型脊柱关节炎患者BASMI五项指标的准确性。 2. 次要研究目的: A. 建立中国正常人群及中轴型脊柱关节炎患者脊柱活动度参考标准。 B. 探索自动化BASMI系统在正常人群和中轴型脊柱关节炎患者中的可靠性差异。 3. 探索性研究目的: A. 分析该系统在疾病活动度监测中的临床应用潜力:研究自动化BASMI系统是否能帮助医生进行疾病进展的动态监测,提高临床决策的及时性与准确性。 B. 探索该系统在远程医疗中的应用前景:评估自动化测量系统是否可以在远程医疗平台上应用,帮助医生实时跟踪患者的病情变化,促进远程医疗服务的发展。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Primary Research Objective: To validate the accuracy of an automated BASMI measurement system based on image processing technology in assessing the five BASMI indicators in patients with axial spondyloarthritis. 2. Secondary Research Objectives: A. Establish reference standards for spinal mobility in the Chinese normal population and patients with axial spondyloarthritis. B. Investigate differences in the reliability of the automated BASMI system between the normal population and patients with axial spondyloarthritis. 3. Exploratory Research Objectives: A. Analyze the clinical application potential of the system in monitoring disease activity: Investigate whether the automated BASMI system can assist physicians in dynamically monitoring disease progression, improving the timeliness and accuracy of clinical decision-making. B. Explore the prospects of the system in telemedicine: Evaluate whether the automated measurement system can be applied on telemedicine platforms to help physicians track patients' condition changes in real time and promote the development of telemedicine services. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
中轴型脊柱炎关节炎患者入选标准: 1. 年龄要求:年龄在18至75周岁(包括临界值,签署知情同意书时为准)的男性或女性受试者。 2. 疾病诊断:符合2009年ASAS推荐的中轴型脊柱关节病(SpA)分类标准。患者应具备以下条件:起病年龄小于45岁,并且有持续超过3个月的腰背痛症状;同时满足下列之一: a) 影像学提示骶髂关节炎:MRI显示有急性(活动性)炎症,或根据1984年修订的纽约标准,影像学确诊骶髂关节炎;且伴随至少一种其他SpA特征。 b) HLA-B27阳性:且伴随至少两种其他SpA特征。 SpA特征:包括但不限于以下症状和体征:炎性背痛;关节炎;跟腱炎;眼葡萄膜炎;指(趾)炎;银屑病;克罗恩病或溃疡性结肠炎;对非甾体抗炎药(NSAIDs)有良好反应;SpA家族史;HLA-B27阳性;C反应蛋白(CRP)升高。 3. 知情同意:受试者必须充分了解研究的内容、目的,并能够按照计划完成研究。自愿参与并能够签署知情同意书。 正常对照的入选标准: 1. 年龄要求:年龄在18至75周岁(包括临界值,签署知情同意书时为准)的男性或女性受试者。 2. 健康状态:正常对照组的受试者应无任何脊柱关节炎等相关疾病的历史。 3. 知情同意:受试者必须充分了解研究内容、目标和特征,并能够按照计划完成研究。自愿参与并能够签署知情同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
Inclusion Criteria for Patients with Axial Spondyloarthritis: 1. Age Requirement: Male or female subjects aged 18 to 75 years (inclusive, at the time of signing the informed consent form). 2. Disease Diagnosis: Fulfill the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis (SpA). Patients must have: onset of symptoms before age 45 and chronic back pain for ≥3 months; and meet one of the following: a) Sacroliitis on Imaging: Active (acute) inflammation on MRI highly suggestive of sacroiliitis associated with SpA, OR definite radiographic sacroiliitis according to the modified 1984 New York criteria; and at least one other SpA feature. b) HLA-B27 Positivity: Positive for HLA-B27 and at least two other SpA features. SpA features include, but are not limited to: Inflammatory back pain; Arthritis; Enthesitis (heel); Uveitis; Dactylitis; Psoriasis; Crohn's disease or ulcerative colitis; Good response to NSAIDs; Family history of SpA; HLA-B27 positivity; Elevated C-reactive protein (CRP). 3. Informed Consent: Subjects must fully understand the content, purpose of the study, be able to complete the study per protocol, voluntarily participate, and be capable of signing the informed consent form. Inclusion Criteria for Normal Controls: 1. Age Requirement: Male or female subjects aged 18 to 75 years (inclusive, at the time of signing the informed consent form). 2. Health Status: Normal control subjects should have no history of any related diseases such as spondyloarthritis. 3. Informed Consent: Subjects must fully understand the content, objectives, and characteristics of the study, be able to complete the study per protocol, voluntarily participate, and be capable of signing the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1. 不愿签署知情同意书:拒绝参与或无法自愿签署知情同意书的患者。 2. 主要脏器功能异常:如心力衰竭、肝功能异常或肾功能不全的患者。 3. 合并恶性肿瘤:有恶性肿瘤病史或正在治疗的患者。 4. 孕妇或哺乳期患者:孕妇或处于哺乳期的女性。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Unwillingness to provide informed consent: Patients who decline to participate or are unable to provide voluntary informed consent. 2. Significant dysfunction of major organs: Patients with conditions such as heart failure, abnormal liver function, or renal insufficiency. 3. Concomitant malignancy: Patients with a history of or currently undergoing treatment for malignant tumors. 4. Pregnancy or lactation: Women who are pregnant or breastfeeding at the time of screening. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-02-28 00:00:00至 To 2028-02-29 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-02-28 00:00:00 至 To 2028-02-29 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
不涉及 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
NONE |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
No sharing |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
1) 数据录入与核查:受试者的所有数据均记录在病例报告表、原始病历中,并保留所有检查报告,确保数据真实;双人核查:由两人交叉核对样本(图像与人工记录匹配性)。 2) 数据存档与安全:图像数据去除面部特征(如使用马赛克)。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data Entry and Verification: All subject data are recorded in case report forms (CRFs) and source medical records, with all examination reports retained to ensure data authenticity. Dual Verification: Two individuals cross-check samples (matching images with manual records). Data Archiving and Security: Facial features in image data are removed (e.g., by pixelation or blurring). |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |